Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. (scientific article published on 12 October 2017)

Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus

Q28302762

Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies

Q28602877

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Q29547347

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases

Q29615069

Broad neutralization coverage of HIV by multiple highly potent antibodies

Q29615361

Chimeric antigen receptor T cells for sustained remissions in leukemia

Q29617588

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

Q29619511

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Q29622949

Autocrine production of beta-chemokines protects CMV-Specific CD4 T cells from HIV infection

Q33513965

Stabilized human TRIM5α protects human T cells from HIV-1 infection

Q33724266

HIV sequence variation associated with env antisense adoptive T-cell therapy in the hNSG mouse model

Q33822232

Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy

Q33843388

Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection

Q33869806

HIV preferentially infects HIV-specific CD4+ T cells

Q33958893

The basic principles of chimeric antigen receptor design

Q34036213

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

Q34046198

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

Q34073529

The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex.

Q34116192

Memory CD8 T-cell differentiation during viral infection

Q34152220

CD4 on CD8(+) T cells directly enhances effector function and is a target for HIV infection

Q34514930

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex

Q34709433

Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy

Q35035926

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells

Q35202343

Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells

Q35328354

Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes

Q35635344

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Q35690389

Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity

Q35745453

Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis

Q35980019

A mutant retroviral receptor restricts virus superinfection interference and productive infection

Q36162599

Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus

Q36195192

Productive infection of neonatal CD8+ T lymphocytes by HIV-1.

Q36400552

Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule.

Q36404652

Stimulation of heterologous protein degradation by the Vpu protein of HIV-1 requires the transmembrane and cytoplasmic domains of CD4

Q72203222

4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulation-dependent rescue of functionally impaired HIV-specific CD8 T cells

Q80139532

The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

Q36408432

Structured treatment interruptions--new findings

Q36583322

Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells

Q36598618

Cell fusion mediated by interaction of a hybrid CD4.CD8 molecule with the human immunodeficiency virus type 1 envelope glycoprotein does occur after a long lag time

Q36654246

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

Q36709308

HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells

Q36757040

Several CD4 domains can play a role in human immunodeficiency virus infection in cells

Q36797775

Cluster of differentiation antigen 4 (CD4) endocytosis and adaptor complex binding require activation of the CD4 endocytosis signal by serine phosphorylation

Q36845470

New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma

Q36891848

Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha

Q36949816

Strength of PD-1 signaling differentially affects T-cell effector functions.

Q36990852

Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.

Q37410726

Implications of Nef: host cell interactions in viral persistence and progression to AIDS.

Q37655448

Novel cell and gene therapies for HIV.

Q38048762

Unravelling the mechanisms of durable control of HIV-1.

Q38116710

Adoptive immunotherapy for cancer or viruses

Q38178359

The pharmacology of second-generation chimeric antigen receptors.

Q38541019

Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells

Q40351372

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

Q40965523

Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor

Q41410840

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Q41429394

Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides

Q41691479

Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects

Q41750120

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

Q42938990

A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy

Q44165805

Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors.

Q44404928

Lack of CD28 expression on HIV-specific cytotoxic T lymphocytes is associated with disease progression

Q44525253

Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection

Q45741637

Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor.

Q46010300

Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning

Q46683819

P275

Creative Commons Attribution 4.0 International

copyrighted

issue

page(s)

e1006613

P577

publication date

2017-10-12

P1433

published in

PLOS Pathogens

Q283209

P1476

title

Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor

P478

volume

Reverse relations

cites work (P2860)

Q96306123	A Trispecific Anti-HIV Chimeric Antigen Receptor Containing the CCR5 N-Terminal Region
Q90227229	Adult and cord blood-derived high affinity gB-CAR-T cells effectively react against human cytomegalovirus infections
Q90639885	Advances in Developing CAR T-Cell Therapy for HIV Cure
Q102056914	Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals
Q91868621	CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases
Q90475786	CAR T cells for infection, autoimmunity and allotransplantation
Q98460330	CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies
Q90705235	CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
Q92857870	CD8+ T-Cell Response to HIV Infection in the Era of Antiretroviral Therapy
Q64058868	Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-stimulatory Signal Domain Exhibits High Functional Potency
Q59359586	Chimeric antigen receptor T-cell approaches to HIV cure
Q55255737	Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments.
Q99637221	Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo
Q91973569	Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches
Q99237937	Engineering CAR T Cells to Target the HIV Reservoir
Q92245174	Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model
Q64109055	Gene Therapy Approaches to Functional Cure and Protection of Hematopoietic Potential in HIV Infection
Q58604627	Genetic Strategies for HIV Treatment and Prevention
Q90244982	HIV-1-Specific CAR-T Cells Fail to Recognize and Eliminate the Follicular Dendritic Cell (FDC) HIV Reservoir In Vitro
Q95847922	HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo
Q88402221	Hard-to-kill macrophages lead to chronic inflammation in HIV
Q52571192	Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA.
Q64231610	Highlights from the Fourth Biennial Strategies for an HIV Cure Meeting, 10-12 October 2018, Bethesda, MD, USA
Q92482546	Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model
Q90197782	Next-generation regulatory T cell therapy
Q91642187	Optimizing intracellular signaling domains for CAR NK cells in HIV immunotherapy: a comprehensive review
Q92912382	Strong In Vivo Inhibition of HIV-1 Replication by Nullbasic, a Tat Mutant
Q48505361	The B-Cell Follicle in HIV Infection: Barrier to a Cure
Q55078034	The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer.
Q60046873	Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction
Q90474772	Toward the Cure of HIV-1 Infection: Lessons Learned and Yet to be Learned as New Strategies are Developed
Q50025140	Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains.
Q92097620	Why and where an HIV cure is needed and how it might be achieved

P356	DOI	10.1371/JOURNAL.PPAT.1006613
P8608	Fatcat ID	release_hjhms27b5va4lnqlghc4oghrau
P932	PMC publication ID	5638568
P698	PubMed publication ID	29023549